Macrophage migration inhibitory factor in pediatric patients undergoing surgery for congenital heart repair

Molecular Medicine

Volumn 14, Issue 3-4, 2008, Pages 124-130

  Merchant, Sanah ^a   Nadaraj, Sumekala ^b   Chowdhury, Devyani ^c   Parnell, Vincent A ^a   Sison, Cristina ^d,e   Miller, Edmund J ^e   Ojamaa, Kaie ^a,e  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Biostatistics Unit   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; OXYGEN; THYROXINE;

ARTICLE; ARTIFICIAL VENTILATION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE VOLUME; HEART SURGERY; HUMAN; INFANT; INFORMATION PROCESSING; INTENSIVE CARE; INVASIVE PROCEDURE; MACROPHAGE MIGRATION; MALE; OXYGEN BREATHING; PATIENT CARE; PATIENT MONITORING; PEDIATRICS; PERIOPERATIVE PERIOD; PLASMA; POSTOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; CARDIOPULMONARY BYPASS; CHILD, PRESCHOOL; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INTERLEUKIN-8; INTRAOPERATIVE PERIOD; MACROPHAGE MIGRATION-INHIBITORY FACTORS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; THYROXINE; TREATMENT OUTCOME;

EID: 41649104647     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00086.Merchant     Document Type: Article

References (34)

1. Casey WF, et al. (1992) Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit. Care Med. 20:1090-6.
2. Hirai S. (2003) Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass. Ann. Thorac. Cardiovasc Surg. 9:365-70.
3. Varan B, Tokel K, Mercan S, Donmez A, Aslamaci S. (2002) Systemic inflammatory response related to cardiopulmonary bypass and its modification by methyl prednisolone: high dose versus low dose. Pediatr. Cardiol. 23:437-41.
4. Kawamura T, Wakusawa R, Okada K, Inada S. (1993) Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J. Anaesth. 40:1016-21.
5. Sablotzki A, et al. (1997) Alterations of the cytokine network in patients undergoing cardiopulmonary bypass. Perfusion 12:393-403.
6. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O. (2001) Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med. 27: 1187-93.
7. Calandra T, Roger T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3:791-800.
8. Garner LB, et al. (2003) Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am. J. Physiol. 285:H2500-9.
9. Fukuzawa J, et al. (2002) Contribution of macrophage migration inhibitory factor to extracellular signal-regulated kinase activation by oxidative stress in cardiomyocytes. J. Biol. Chem. 277:24889-95.
10. Yu C-M, Lai KW-H, Chen Y-X, Huang X-R, Lan HY. (2003) Expression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J. Histochem. Cytochem. 51:625-31.
11. Takahasi M, et al. (2001) Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc. Res. 52:438-45.
12. de Mendonca-Filho HTF, Gomes RV, de Almeida Campos LA, Castro-Faria-Neto HC, Tura B, Nunes EM, Castro-Faria-Neto HC. (2004) Circulating levels of macrophage migration inhibitory factor are associated with mild pulmonary dysfunction after cardiopulmonary bypass. Shock 22:533-7.
13. de Mendonca-Filho HTF, Pereira KC, Fontes M, de Souza Aranha Vieira DA, de Mendonca MLA, de Almeida Campos LA, Castro-Faria-Neto HC. (2006) Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study. Crit. Care 10:46.
14. Gando S, Nishihira J, Kemmotsu O, Kobayashi S, Morimoto Y, Matsui Y, Yasuda K. (2000) An increase in macrophage migration inhibitory factor release in patients with cardiopulmonary bypass surgery. Surg. Today 30:689-94.
15. Lin X, Sakuragi T, Metz CN, Ojamaa K, Wang P, Skopicki H, Al-Abed Y, Miller EJ. (2005) Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis. Shock 24: 556-563.
16. Sakuragi T, Lin X, Metz CN, Ojamaa K, Kohn N, Al-Abed Y, Miller EJ. (2007) Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg. Infect. 8:29-40.
17. Chagnon F, Metz CN, Bucala R, Lesur O. (2005) Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization. Circ. Res. 96:1095-1102.
18. Madhok AB, Ojamaa K, Viraga H, Parnell VA, Pahwa S, Chowdhury D. (2006) Cytokine response in children undergoing surgery for congenital heart disease. Pediatr. Cardiol. 27:408-13.
19. Chowdhury D, Parnell VA, Ojamaa K, Boxer R, Cooper R, Klein I. (1999) Usefulness of triiodothyronine (T3) treatment after surgery for complex congenital heart disease in infants and children. Am. J. Cardiol. 84:34-36.
20. Chowdhury D, Ojamaa K, Parnell VA, McMahon CK, Sison CP, Klein I. (2001) A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease. J. Thorac. Cardiovasc. Surg. 122:1023-5.
21. McMahon CK, Klein I, Ojamaa K. (2003) Interleukin-6 and thyroid hormone metabolism in pediatric cardiac surgery patients. Thyroid 13:301-4.
22. Keene AR, Cullen DJ. (1983) Therapeutic intervention scoring system: update 1983. Crit. Care Med. 11:1-3.
23. Wernovsky G, Wypij D, Jonas RA, et al. (1995) Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 92:2226-35.
24. Bland JM, Altman DG (1995) Calculating correlation coefficients with repeated observations: part I, correlation within subjects. Br. Med. J. 310:446.
25. Butler J, et al. (1996) Acute-phase responses to cardiopulmonary bypass in children weighing less than 10 kilograms. Ann. Thorac. Surg. 62:538-42.
26. Casey LC. (1993) Role of cytokines in the pathogenesis of cardio-pulmonary-induced multisystem organ failure. Ann. Thorac. Surg. 56:S92-6.
27. Gessler P, Pfenninger J, Pfammatter JP, Carrel T, Dahinden C. (2002) Inflammatory response of neutrophil granulocytes and monocytes after cardiopulmonary bypass in pediatric cardiac surgery. Intensive Care Med. 28(12):1786-91.
28. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759.
29. Calandra T, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71.
30. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6; 164-70, 2000.
31. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY. (2003) Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J. Pathol. 199:496-508.
32. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. (1995) Effects of thyroid hormone supplementation in cardiac surgery. N. Engl. J. Med. 333:1522-7.
33. Klemperer JD, Klein I, Ojamaa K, Helm R, Gomez M, Isom W, Krieger K. (1996) Triiodothyronine decreases atrial fibrillation after coronary artery bypass surgery. Ann. Thoracic Surg. 61:1323-1329.
34. Mann DL. (2002) Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circ. Res. 91:988-998.